Paul Reider
Corporate Officer/Principal presso COHERUS BIOSCIENCES, INC.
Patrimonio netto: 194 252 $ in data 31/03/2024
Posizioni attive di Paul Reider
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 | - |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Storia della carriera di Paul Reider
Precedenti posizioni note di Paul Reider
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 01/01/2019 | 01/01/2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - | - |
Formazione di Paul Reider
| Bowling Green State University | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Canada | 2 |
Posizioni
| Corporate Officer/Principal | 3 |
| Sales & Marketing | 1 |
| Masters Business Admin | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
- Borsa valori
- Insiders
- Paul Reider
- Esperienza
